Synergy CHC Corp. (SNYR) Fair Value 2026

SNYR · Medicinal Chemicals & Botanical Products ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.8 /10

32 fundamental signals · 4 models active

Value Trap Risk

SAFE (14/100)

Quick Summary — As of 2026-07-13, Synergy CHC Corp. (SNYR) trades at $0.19. QOC: 5.8/10. Value Trap Risk: 14/100 (SAFE). 4/13 models active.

Key Facts

Ticker
SNYR
Price
$0.19
Quality Score
5.8/10
Value Trap Risk
14/100
Models Active
4/13
Last Updated
Strength: Markov DDM suggests +368.6% upside with 29% confidence
Risk: Limited model coverage (4/13) may reduce confidence

Valuation Matrix

4 Intrinsic Value Models vs. Current Price ($0.19)

Core Models (Unlocked)
Model Fair Value Upside
RCMH-DCF
Medium Conviction
 $0.23 +21.1%
Markov DDM
Medium Conviction
 $0.91 +368.6%

Unlock the Full Matrix

Access 2 additional models including EROIC Spread, ML-RIV.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 4 Models →

Cancel anytime · No contracts · Instant access

What Is Synergy CHC Corp. (SNYR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Synergy CHC Corp. is potentially undervalued at its current price of $0.19. Based on our 13-model framework, Synergy CHC Corp.'s intrinsic value is estimated at a composite fair value of $0.57 — representing +194.7% implied upside — with 4 out of 4 active models confirming this thesis. Model dispersion is worth noting: Markov DDM targets $0.91 (+368.6%), versus RCMH-DCF at $0.23 (+21.1%). This +347.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SNYR?

4 of 13 models are currently active for SNYR. All 4 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does SNYR Rank in Medicinal Chemicals & Botanical Products?

Among 17 Medicinal Chemicals & Botanical Products stocks, SNYR ranks #8 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.

Synergy CHC Corp.'s positioning within the Medicinal Chemicals & Botanical Products segment means that book-to-bill ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including electrification tailwinds — shape both the opportunity set and risk profile.

Is SNYR a Value Trap?

CirclFi's Value Trap algorithm assigns SNYR a score of 14/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

4 of 13 models are active for Synergy CHC Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Synergy CHC Corp. earns a quality score of 5.8/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +347.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SNYR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SNYR's 4 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Synergy CHC Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medicinal Chemicals & Botanical Products Stocks Should You Also Analyze?

8 related Medicinal Chemicals & Botanical Products stocks with 13-model coverage

NAGENiagen Bioscience, Inc.QOC 9.2FTLFFitLife Brands, Inc.QOC 9.1USNAUSANA Health Sciences, Inc.QOC 7.6BTMDBiote Corp.QOC 6.7TLRYTilray Brands, Inc.QOC 6.4MTEXMannatech, IncorporatedQOC 6.3NAIINatural Alternatives InternatioQOC 6.2SNDLSNDL Inc.QOC 5.5

Read investment analysis: NAGE · FTLF · USNA · BTMD · TLRY

Frequently Asked Questions About Synergy CHC Corp.

What is Synergy CHC Corp.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Synergy CHC Corp. (SNYR) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value. The Quality of Company score is 5.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SNYR overvalued or undervalued right now?

At $0.19, 4 of 4 active models suggest SNYR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Synergy CHC Corp.'s business model in Medicinal Chemicals & Botanical Products.

What does a Quality of Company score of 5.8 mean for SNYR?

Synergy CHC Corp.'s QOC of 5.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SNYR?

CirclFi analyzes SNYR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 4 of 13 are active for this stock. Read the full methodology →

Is SNYR a value trap in 2026?

Synergy CHC Corp.'s Value Trap score is 14/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 4 mathematical frameworks give you clarity on SNYR.

Unlock All 4 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access